Clinical Trial Search

Primary: Change in Response Rates of nAb Responses to the Vaccine Strains and a Global Panel of Heterologous Env-pseudotyped Viruses

Primary: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞) of Sitravatinib — 2524.7; 2892.6 h*ng/mL

Primary: Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax]) — 57.2; 41.7; 46.5; 22.3 ng/mL — p=0.803

Primary: Maximum Serum Concentration (Cmax) of TCZ — 197; 178 ug/mL

Primary: Number of Patients With Dose-limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin 15 (IL-15) (rhIL-15) — 2 mcg/kg/day

Primary: Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Deaths — 0; 1; 1; 2 Participants

Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants

Primary: Imipenem (IMI) Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-∞) — 134.7; 153.2; 219.4; 139.4 μM*hr

Primary: Part A: Number Of Participants Experiencing Adverse Events (AEs) — 12; 12; 6; 13 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug — 0; 0; 0; 0 Participants

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Tlast (AUC[0-tlast]) of LY3832479 — 1560; 4530 microgram*day per milliliter…

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3819253 — NA; 918; 1390 micrograms*day per…

Primary: Percentage of Participants Who Experienced an Adverse Event (AE) up to Day 56 — 92.9; 92.9; 91.7; 62.5 Percentage of Participants — p== 0.2003